Pharmacogenomics (PGx) Cardiovascular Panel
An 11-gene pharmacogenomic panel for optimizing cardiovascular drugs including anticoagulants, antiarrhythmics, antihypertensives, antiplatelets, beta blockers, and statins, powered by the Helix Exome+® platform.
Turnaround
6-9 days
Requery (SOQO)
≤ 5 minutes
Genes Tested
11
Panel Description
Many medications used to treat cardiovascular conditions are impacted by specific variations in known genes. These genetic variations can contribute to medication efficacy and risk for side effects. Pharmacogenomic testing to guide prescribing, paired with clinical monitoring can impact outcomes for patients by reducing the time to therapeutic effect and reducing the risk of side effects.
Order This Test
Contact our clinical team to order this panel or learn more.
Indications for Testing
Patients for whom cardiovascular medications are being considered, have been ineffective or caused side effects.
Methodology
This test utilizes next-generation sequencing to determine results for ABCB1, ABCG2, CYP2C cluster, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP4F2, GRK4, SLCO1B1, and VKORC1.
Technical Specifications
Reportable range
ABCB1: rs2032582, rs1128503, rs1045642; ABCG2: rs2231142; CYP2C cluster: rs12777823; CYP2C9: *1-*61; CYP2C19: *1-*19, *22-*26, *28-*39; CYP2D6: *1-*15, *4N, *17-*65, *68-*75, *81, *83-*114; CYP3A4: *1-*24, *26, *28-*38; CYP4F2: *1,*3; GRK4: rs1024323; SLCO1B1: *1-*16, *19, *20, *23-*34, *36-*44, *47-*49; VKORC1: rs9923231
Technical note
Sensitivity may be reduced for the CYP2D6*13 allele.
Genes Tested
11 genes included in this panel
Ordering Information
Turnaround Time
Typically 6-9 days (standard), Typically ≤ 5 minutes (requery)
Preferred Specimen
BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions
Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
Clinical Description
Many medications used to treat cardiovascular conditions are impacted by specific variations in known genes. These genetic variations can contribute to medication efficacy and risk for side effects. Pharmacogenomic testing to guide prescribing, paired with clinical monitoring can impact outcomes for patients by reducing the time to therapeutic effect and reducing the risk of side effects.
This panel evaluates 11 genes associated with response to drugs prescribed to treat cardiovascular disease, including anticoagulants, antiarrhythmics, antihypertensives, antiplatelets, beta blockers, and HMG-CoA Reductase Inhibitors (statins). Results from this test may help in predicting treatment efficacy and risk of side effects for these drugs.
Ready to order this test?
Contact our clinical team to order the Pharmacogenomics (PGx) Cardiovascular Panel for your patients.